# HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

> **NCT06391710** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 203 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** HRS9531
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06391710
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391710, "HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06391710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*